http://www.pharmacist.com/article/dea-mandates-reduction-opioid-manufacturing-2018 Over objections that limits could harm chronic pain patients, agency moves forward with cuts DEA’s finalized annual aggregate production quotas (APQs) for 2018 mandate a 20% reduction in the amount of opiate and opioid medication—including oxycodone, hydrocodone, oxymorphone, hydromorphone, morphine, codeine, meperidine, and fentanyl—that may be manufactured in 2018. Quotas are aimed at preventing […]
Filed under: General Problems | 2 Comments »